Thus, in bladder cancer, this ex vivo assay can potentially be used to identify a group of patients that might benefit from precision anti-cancer treatments directed against HR-defective tumors (i. e. PARP-1 inhibition) [45]. The gene discussed is PARP1; the disease is urinary bladder carcinoma.